Gynecological Cancer Clinical Trials

Trial  #

Trial Sub-type            

Title

GOG – 0263
NCI

Cervical Cancer, Stage I-IIA, Previously Underwent Surgery

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

C14008
Millennium, Inc.

Patients with ovarian cancer who have a treatment-free interval ≤ 12 months after platinum therapy or patients who experience persistent or recurrent disease during platinum therapy and who are candidates for treatment with weekly paclitaxel

Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer

GOG–0262
NCI

Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

A Randomized Phase III Trial of Every-3-weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Caboplatin Plus Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Yale University School of Medicine

 Surgically Staged III-IV (TAH/BSO/Washings/PPAL D) or Recurrent Uterine Serous Papillary Carcinoma Patients with Measurable Disease Surgically Staged III-IV (TAH/BSO/Washings/PPAL D) or Recurrent Uterine Serous Papillary Carcinoma Patients with Measurable Disease

A Randomized Phase III Evaluation of Carboplatin/paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with advanced/Recurrent Uterine Serous Papillary Carcinoma

 GOG 0258

Advanced Endometrial Carcinoma

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma